| Entry inhibitor: maraviroc (Selzentry) | None | None | Cough, fever, upper respiratory symptoms, rash, abdominal pain, orthostatic hypotension, musculoskeletal symptoms; hepatotoxicity may be associated with rash and eosinophilia; increased risk of myocardial infarction (1.3%) compared with placebo in 24-week study17 |
| Fusion inhibitor: enfuvirtide (Fuzeon) | None | None | Injection site reactions, eosinophilic hypersensitivity reactions (less than 1%) and neutropenia; may increase risk of bacterial pneumonia |
| Integrase strand transfer inhibitor: raltegravir (Isentress) | None | None | Diarrhea, nausea, headache, increased creatine kinase levels, myopathy, rhabdomyolysis |
